Google
Trusted Resources: News & Events
Latest announcements and gatherings
HHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell Disease
By 2029, Americans with sickle cell disease (SCD) could be living 10 years longer than they do today, predicts U.S. Health and Human Services Secretary Alex Azar.
That’s one of the Trump administration’s long-term goals, Azar — the nation’s top health official — told more than 900 delegates attending the 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit in Washington, D.C.
The recent summit, organized by the National Organization for Rare Disorders, also featured speeches by Norman E. “Ned” Sharpless, MD, acting commissioner of the U.S. Food and Drug Administration (FDA), and his predecessor, former FDA Commissioner Scott Gottlieb, MD. In his 17-minute speech, Azar used SCD as an example of President Trump’s commitment to those with rare diseases.
+myBinderRelated Content
-
Amerindian/Asian Ancestry and Mortality Are Associated with Allo-Immunization in Adults with Sickle Cell Disease in ...Background: Transfusion is a standard th...
-
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Effi...Background: Hydroxyurea prevents disea...
-
In France, Boy Becomes First Sickle Cell Disease Patient to be Treated With Gene TherapyA 13-year-old boy with sickle cell disea...
-
Alabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
-
Gene Therapy & Clinical Trials Webinarhttps://www.youtube.com/watch?v=yYexIUgH...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.